2012 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC)

2012 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) | CMSC 2012

The focus of the 2012 Annual Meeting of the CMSC is "to provide MS healthcare professionals with the most up-to-date information impacting patient care in the areas of research, disease modification, epidemiology, quality of life, neuroimaging, gender specific issues..." and more. Highlights from the conference will include case-based learning, technological advances in clinical care and research, clinical care, and basic research and clinical trials.

Conference Coverages

CMSC 2012: Oral Teriflunomide Not Superior to Interferon in Risk of Treatment Failure
The oral disease-modifying drug under development for the treatment of relapsing-remitting multiple sclerosis, teriflunomide, was not superior to interferon beta-1a in risk of treatment failure.
CMSC 2012: Immune Parameters Normalize Within 4 Months of Natalizumab Cessation in the Treatment of RRMS
In the course of a 24-week cessation of treatment with the humanized monoclonal antibody, natalizumab, in patients with RRMS, pharmacokinetic, pharmacodynamic, and serum immune parameters normalized by 4 months.
CMSC 2012: Ischemic Heart Disease and Myocardial Infarction Occur Less Frequently in Hospital Discharges with Multiple Sclerosis
People discharged from the hospital with MS are 30% less likely to have had a myocardial infarction and 58% less likely to have ischemic heart disease.
CMSC 2012: Dimethyl Fumarate Improves Annualized Relapse Rate and Risk of Relapse in Patients With RRMS
Treatment with the investigational oral treatment for relapsing-remitting multiple sclerosis, dimethyl fumarate (aka BG-12), yielded significant reductions in the annualized relapse rate and risk of relapse.
CMSC 2012: Natalizumab Interruption Results in a High Rate of MRI and Clinical MS Disease Activity Recurrence
After a 24-week cessation of natalizumab treatment, a high rate of MRI and clinical disease activity recurs in patients with multiple sclerosis.
CMSC 2012: Alemtuzumab Efficacy in RRMS Patients Who Relapsed on Prior Therapy
The monoclonal antibody, alemtuzumab, significantly reducesthe number of relapses and the accumulation of disability in patients with relapsing-remitting multiple sclerosis who had relapsed on prior therapy.
CMSC 2012: Fingolimod Slows Brain Volume Loss and May Be Neuroprotective
The once-daily oral MS drug, fingolimod, slows brain volume loss in patients with MS, regardless of inflammatory activity.
CMSC 2012: Fingolimod Significantly Reduces Relapse Rates in MS Patients, Regardless of Duration of or Reasons for Discontinuing Prior Therapy
The once-daily oral MS drug, fingolimod, reduces annualized relapse rates in patients who achieved unsatisfactory responses when treated with other disease-modifying therapies or who had been treated for an extended period of time.
CMSC 2012: Dimethyl Fumarate Significantly Improves Number and Volume of Lesions on MRI in Relapsing-Remitting MS
Treatment with the investigational oral drug for RRMS, dimethylfumarate (aka BG-12), yielded significant reductions in inflammatory disease activity using MRI outcomes.

Most Popular


$vacMongoViewPlus$ $vAR$